In the HBV-related HCC cell line, HepG2.2.15, miR-122 inhibited viral replication by targeting NDRG3, a member of the N-myc downstream-regulated gene family [32], suggesting that both miRNA-122 and NDRG3 are viable therapeutic targets for HBV-related HCC. The gene discussed is NDRG3; the disease is hepatocellular carcinoma.